VYGR -14%/AH on new FDA clinical hold: https://www.globenewswire.com/news-release/2020/12/22/2149712/0/en/Voyager-Therapeutics-Provides-Update-on-NBIb-1817-VY-AADC-Gene-Therapy-Program.html